ReviewAmerican journal of cancer research2018
The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug.
Review in American journal of cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
106 citing papers in PubMed, 2 syntheses or guidelines pooled it, 184 citations in OpenAlex.
- Ivermectin, a potential anticancer drug derived from an antiparasitic drug.Pharmacological research · 2021Pooled it
- Ivermectin and mortality in patients with COVID-19: A systematic review, meta-analysis, and meta-regression of randomized controlled trials.Diabetes & metabolic syndromePooled it
- Different gut microbial communities correlate with efficacy of albendazole-ivermectin against soil-transmitted helminthiases.Nature communications · 2022Trial
- Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-blind, Randomized, Controlled Clinical Trial.Clinical therapeutics · 2021Trial
- Pharmacokinetics of ascending doses of ivermectin in Trichuris trichiura-infected children aged 2-12 years.The Journal of antimicrobial chemotherapy · 2019Trial
- Effects of Three Anthelmintics on the Transcriptome of FHs 74 Int Enterocytes.Tropical medicine and infectious disease · 2026Article
- Article
- Repurposing therapies in junctional epidermolysis bullosa: Oral ivermectin therapy associated with improved wound healing and reduced pruritus.JAAD case reports · 2026Article
- Captivating Synergistic, Dose-Dependent Anticancer Effects of Tumor-Regulation Modulators Chloroquine and Ivermectin Completely Abolished by an Opposing Modulator, Deoxycholic Acid, in Hamster Fibrosarcoma: In Vivo, In Vitro, and Literature Review.Pharmaceuticals (Basel, Switzerland) · 2026Article
- The Nodding syndrome cerebrospinal fluid proteome: a lens into neurodevelopmental failure consistent with environmentally triggeredFrontiers in molecular neuroscience · 2026Article
- Therapeutic and Formulation Advances of Ivermectin in Veterinary and Human Medicine.Pharmaceutics · 2025Review
- Ivermectin as an Alternative Anticancer Agent: A Review of Its Chemical Properties and Therapeutic Potential.Pharmaceuticals (Basel, Switzerland) · 2025Review
- High-throughput in vitro drug screening and in vivo studies identify fenretinide as a brain-penetrant DMG therapeutic.Neuro-oncology · 2025Article
- Ivermectin inhibits replication of porcine deltacoronavirusJournal of veterinary science · 2025Article
- High Efficacy of Triclabendazole/Ivermectin Combination Compared to Triclabendazole Monotherapy for Treating Human Fascioliasis in Upper Egypt: A Prospective Study.Tropical medicine and infectious disease · 2025Article
- Article
- Intranasal Delivery of Ivermectin Nanosystems as an Antitumor Agent: Focusing on Glioma Suppression.ACS biomaterials science & engineering · 2025Article
- Apoptosis-Inducing and Proliferation-Inhibiting Effects of Doramectin on Mz-ChA-1 Human Cholangiocarcinoma Cells.International journal of molecular sciences · 2024Article
- Pharmacoproteomics reveals energy metabolism pathways as therapeutic targets of ivermectin in ovarian cancer toward 3P medical approaches.The EPMA journal · 2024Article
- Ivermectin inhibits the growth of ESCC by activating the ATF4-mediated endoplasmic reticulum stress-autophagy pathway.Acta biochimica et biophysica Sinica · 2024Article
46 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug repositioning is a highly studied alternative strategy to discover and develop anticancer drugs. This drug development approach identifies new indications for existing compounds. Ivermectin belongs to the group of avermectins (AVM), a series of 16-membered macrocyclic lactone compounds discovered in 1967, and FDA-approved for human use in 1987. It has been used by millions of people around the world exhibiting a wide margin of clinical safety. In this review, we summarize the
Indexed as
Identifiers
29511601PMC5835698W2981366800What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.